All Articles by Author:
Bob
Newsletters
Endometrial Cancer PDX-Derived Organoids (PDXOs) and PDXs with FGFR2c Isoform Expression Are Sensitive to FGFR Inhibition
[npj Precision Oncology] Researchers reported the establishment of 16 endometrial cancer (EC) PDXOs with or without FGFR2c expression. In vitro treatment of five EC PDXOs with BGJ398 showed significant cell death in three models with FGFR2c expression.
Newsletters
Single-Cell Transcriptome Profiling of Primary Tumors and Paired Organoids of Pancreatobiliary Cancer
[Cancer Letters] The authors conducted scRNA-seq for paired primary tumors and organoids from one cholangiocarcinoma and two pancreatic ductal adenocarcinoma patients.
Newsletters
Proteome Signatures of Joint Toxicity to Arsenic (as) and Lead (Pb) in Human Brain Organoids with Optic Vesicles
[Environmental Research] Investigators utilized brain organoids with optic vesicles to systematically analyze the neurotoxicity of arsenic and lead.
Newsletters
Pathological Deficit of Cystatin B Impairs Synaptic Plasticity in EPM1 Human Cerebral Organoids
[Molecular Neurobiology] Scientists investigated the involvement of cystatin B in synaptic plasticity, using synaptosomes from human cerebral organoids as well as from rodents’ brain.
Newsletters
3D Hepatic Organoid Production from Human Pluripotent Stem Cells
[Differentiation] Researchers described the stepwise and fully 3D production of hepatic organoids from hPSCs. They optimized every differentiation step by screening for optimal concentrations and timing of differentiation signals in each differentiation step.
Newsletters
Bioprinting Using Organ Building Blocks: Spheroids, Organoids, and Assembloids
[Tissue Engineering Part A] Investigators discuss the expanding range of organ building blocks (OBB), presents the rapidly evolving collection of bioprinting and bioassembly methods using these OBB, and outlines the advantages, challenges, and future perspectives of employing OBB in organ printing.
Popular
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older with pNET and epNET
[FDA] The FDA approved cabozantinib for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
Spermidine Restricts Neonatal Inflammation via Metabolic Shaping of Polymorphonuclear Myeloid-Derived Suppressor Cells
[Journal of Clinical Investigation] Scientists reported that plasma spermidine was correlated with the maturity of human newborns and reduced risk of inflammation. Administration of spermidine led to the remission of neonatal inflammation in mice.
Enhancing Anti-CD3 mAb-Mediated Diabetes Remission in Autoimmune Diabetes through Regulation of Dynamin-Related Protein 1(Drp1)-mediated Mitochondrial Dynamics in Exhausted CD8+T-Cell Subpopulations
[BMC Medicine] The phenotypic and metabolic properties of two subsets of exhausted CD8+ T cells were analyzed in both humans and NOD mice. T-cell receptor (TCR) diversity and Bulk RNA sequencing provided insights into the transcriptomic profiles and TCR reactivity of these cells.